MicroRNA-Based Germline Signature Predicts RT-Induced Genitourinary Toxicity in Prostate Cancer
FRIDAY, April 18, 2025 (HealthDay News) — A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced genitourinary (GU) toxicity in patients with prostate cancer, according to a study
Citrus Oil Formula May Relieve Dry Mouth for Cancer Patients
SATURDAY, March 29, 2025 (HealthDay News) — A new formula made with natural citrus oil could help cancer patients find relief from dry mouth, a common and painful side effect of radiation treatments.
Surgery Not Necessary In Some Early-Stage Breast Cancers, Study Says
MONDAY, March 31, 2025 (HealthDay News) — Surgery might not be needed to treat as many as 60% of early-stage breast cancers, a new study says.
Prostate Cancer Surgery Innovation Preserves Erectile Function
Discover the groundbreaking NeuroSAFE technique that nearly doubles the chances of preserving erectile function in prostate cancer patients post-surgery, without compromising cancer control.
Rapid Gene Test Aids Brain Cancer Surgery
WEDNESDAY, Feb. 26, 2025 (HealthDay News) — A rapid experimental genetic test can help guide the hands of surgeons as they delicately remove tumors from patients with brain cancer, new research suggests.
Testosterone Recovery Linked to Overall Survival in High-Risk Prostate Cancer
TUESDAY, Feb. 18, 2025 (HealthDay News) — Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients with high-risk prostate cancer receiving radiotherapy and long-term androgen deprivation therapy (ADT), according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 13 to 15 in San Francisco.
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
WEDNESDAY, Feb. 19, 2025 (HealthDay News) — For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall survival versus placebo + ENZA, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 13 to 15 in San Francisco.
AI Contributes to Early Detection of Clinically Relevant Breast Cancer
THURSDAY, Feb. 13, 2025 (HealthDay News) — Artificial intelligence (AI) contributes to early detection of clinically relevant breast cancer, according to a study published online Feb. 3 in The Lancet Digital Health.
Urine-Based Test Provides Accurate Testing Option for Advanced Prostate Cancer
The 18-gene MyProstateScore 2.0 (MPS2) test using first-catch non-digital rectal examination (DRE) urine is highly sensitive for grade group (GG) ≥2 prostate cancer and can improve the proportion of biopsies avoided.
The Pill Protects Against Ovarian Cancer, Study Says
WEDNESDAY, Feb. 5, 2025 (HealthDay News) — The Pill prevents pregnancy — and maybe ovarian cancer, too, a new study suggests.
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
THURSDAY, Jan. 30, 2025 (HealthDay News) — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1
Daily Aspirin Reduces Colon Cancer Risk: Study
WEDNESDAY, Jan. 29, 2025 (HealthDay News) — Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new stu
